PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
28819586-0	2017	The cardiac glycoside convallatoxin inhibits the growth of colorectal cancer cells in a p53-independent manner.	Glycosides	12-21	tumor protein p53	Homo sapiens	88-91	
19679550-0	2009	Cardiac glycosides inhibit p53 synthesis by a mechanism relieved by Src or MAPK inhibition.	Glycosides	8-18	tumor protein p53	Homo sapiens	27-30	
19679550-2	2009	We report here that p53, in multiple lines of human cancer cells, is down-regulated by cardiac glycoside drugs digoxin and ouabain, potent inhibitors of Na(+)/K(+)-ATPase.	Glycosides	95-104	tumor protein p53	Homo sapiens	20-23	
19679550-10	2009	This is the first report that cardiac glycoside drugs, by initiating the Src/MAPK signaling pathways, reduce the p53 levels via inhibition of p53 protein synthesis.	Glycosides	38-47	tumor protein p53	Homo sapiens	113-116	
19679550-10	2009	This is the first report that cardiac glycoside drugs, by initiating the Src/MAPK signaling pathways, reduce the p53 levels via inhibition of p53 protein synthesis.	Glycosides	38-47	tumor protein p53	Homo sapiens	142-145	
25193633-3	2014	Recent studies demonstrate that the depletion of p53 and hypoxia-induced factor 1alpha proteins is caused by cardiac glycosides.	Glycosides	117-127	tumor protein p53	Homo sapiens	49-52